Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M28,319Revenue $M1,212Net Margin (%)-65.8Z-Score10.4
Enterprise Value $M27,651EPS $-2.0Operating Margin %-107.1F-Score4
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-117.7Higher ROA y-yY
Price/Book24.310-y EBITDA Growth Rate %0Quick Ratio4.4Cash flow > EarningsY
Price/Sales34.55-y EBITDA Growth Rate %0Current Ratio4.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-22.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-41.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M241ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 111.8518%Reduce -31.99%4,593
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 111.8560%New holding, 6753 sh.6,753
VRTXJohn Burbank 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 111.8560%Sold Out0
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 111.8560%Sold Out0
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 111.8541%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 111.8541%New holding, 10000 sh.10,000
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 111.8541%New holding, 2872 sh.2,872
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 111.8561%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 111.8540%Add 19%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 111.8552%Add 140.58%5,990,000
VRTXAndreas Halvorsen 2013-06-30 Sold Out -0.26%$52.6 - $85.6
($73.64)
$ 111.8552%Sold Out0
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 111.8552%Sold Out0
VRTXAndreas Halvorsen 2013-03-31 Buy 0.26%$41.9 - $54.97
($47.91)
$ 111.85134%New holding, 780500 sh.780,500
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 111.85134%Reduce -23.44%191,032
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 111.85143%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 111.85143%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 111.85109%Add 40%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 111.85109%Reduce -25%150,000
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 111.85109%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 111.85109%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2014-09-3011,807,5004.913.4
VRTX Ken Fisher 2014-09-304,59300-31.99%
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LEIDEN JEFFREY MCEO & President 2014-12-15Sell50,017$114.97-2.56view
SMITH IAN FEVP & CFO 2014-12-12Sell6,042$120.12-6.73view
Connolly ThomasSVP, Human Resources 2014-12-12Sell520$120.06-6.69view
Silva Paul MSVP & Corp Controller 2014-12-12Sell2,813$120.08-6.7view
BOGER JOSHUA SDirector 2014-12-10Sell10,500$119.44-6.2view
Connolly ThomasSVP, Human Resources 2014-12-04Sell937$118.98-5.84view
BOGER JOSHUA SDirector 2014-12-03Sell10,500$119.83-6.51view
Sachdev AmitEVP, Policy, Access & Value 2014-11-28Sell12,000$120-6.64view
Silva Paul MSVP & Corp Controller 2014-11-28Sell8,164$119.85-6.52view
SACHS BRUCE IDirector 2014-11-28Sell10,000$120.03-6.67view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
    Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 

    More From Other Websites
    Where Are They Now? A Look Back at the Best & Worst Biotech CEOs Dec 16 2014
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Change in Directors or Principal Officers Dec 15 2014
    Is This The Future Of Late-Stage Drug Development? Dec 15 2014
    David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief... Dec 15 2014
    David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief... Dec 15 2014
    Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data Dec 10 2014
    Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Dec 03 2014
    Stock Market News for December 03, 2014 Dec 03 2014
    RBC's biotech picks: CELG, BMRN & VRTX Dec 02 2014
    7 Biotech stocks to buy now Dec 02 2014
    Equity markets end lower, though commodity prices staged a huge “squeeze” higher... Dec 01 2014
    Vertex Pharmaceuticals' 52-Week High Driven by Kalydeco Dec 01 2014
    Celgene, BioMarin and Vertex are RBC's Top Biotech Buys Dec 01 2014
    Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Nov 26 2014
    Today's Stocks Driving Success For The Drugs Industry Nov 25 2014
    It was another slow, low volume, lackluster trading session Nov 24 2014
    Vertex to Present at Deutsche Bank BioFEST on December 2 Nov 20 2014
    Vertex to Present at Deutsche Bank BioFEST on December 2 Nov 20 2014
    Insider Trading Alert - LNKD, VRTX And RLGY Traded By Insiders Nov 20 2014
    The S&P failed to extend its 4-day winning streak following headlines out of the Fed Nov 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK